Cipher Pharmaceuticals Inc (CPHRF) reports a remarkable 141% increase in net revenue, driven by strategic acquisitions and robust product performance.

Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that it will release its financial results for the fourth quarter and fiscal 2024 after the market ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Cipher Pharmaceuticals (TSE:CPH) has had a rough three months with its share price down 21%. However, stock prices ...

Investing in Canadian growth stocks such as Cipher and Lumine can help you generate outsized gains in 2025 and beyond. The ...

The considerable ownership by individual investors in Cipher Pharmaceuticals indicates that they collectively have a greater say in management and business strategy A total of 9 investors have a ...

Cipher Pharmaceuticals (TSX: CPH) (OTCQX: CPHRF) is a specialty pharmaceutical company with a robust and diversified portfolio of commercial and early to late-stage products, mainly in dermatology.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...